Introduction: Vancomycin is used in pediatric patients usually at 40 mg/kg/day four times daily. Recent data demonstrated the need of large doses to reach therapeutic concentrations in critical patients.
Objective: Describe dosage regime of vancomycin in patients from a pediatric intensive care unit, register values of plasmatic concentrations and determine the regimes necessary to reach therapeutic troughs. POPULATION, MATERIALS AND METHODS: We made an observational, retrospective study. Patients who received vancomycin by more than two days where studied. Patients who didn't register vancomycin troughs (minimum values) and/or with elevated serum creatinine were excluded. The age, grouping in younger than (<) 2 years and older than (>) 2 years and troughs of vancomycin were registered. Volume of distribution (Vd) and half-life (t 1/2) were obtained. Results. We studied 97 patients. Patients with undetectable plasmatic concentrations younger than two years were 14 and the older ones were 9, this difference was not statistically significant (p= 0.063). Mediam of the regime of administration for the younger group was 50 mg/kg/day each 6 h and for the older 40 mg/kg/day four times a day. Mediam (range) of Vd and half-life (t 1/2) for the group of < 2 years and >2 years were 0.682 (0.504-1.06) L/kg, 6.12 (2.66-17.49) h; 0.685 (0.389-1.198) L/kg, 4.88 (3.59-15.4) h, without significant differences.
Conclusions: Dosage regime required an increase in frequency, in addition there were no significant differences between pharmacokinetic parameters and final administration regime for both groups, being able to suppose that equal schemes of administration could be implemented more frequently.
Download full-text PDF |
Source |
---|
Mol Cell Biochem
January 2025
Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
As several decades of research have shown the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors alone or in combination with diuretics, we were interested in investigating the effects of subchronic therapy of these drugs on ischemia-reperfusion (I/R) damage to the heart, as well as their influence on oxidative status. The research was conducted on 40 spontaneously hypertensive male Wistar Kyoto rats, divided into 4 groups. Animals were treated for four weeks with 10 mg/kg/day zofenopril alone or in combination with hydrochlorothiazide, indapamide and spironolactone per os.
View Article and Find Full Text PDFNutrients
December 2024
Pharmacology Laboratory, Department of Medicine, University of Patras, 26500 Rio Achaia, Greece.
Background/objectives: Lavender has been utilized for its medicinal properties since ancient times, with numerous health benefits reported. This study aimed to valorize solid waste from lavender essential oil production by developing a novel lavender extract from solid lavender residues. The extract's preclinical safety and efficacy were evaluated with emphasis on plasma lipid and lipoprotein metabolism, glucose tolerance, and adipose tissue metabolic activity.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510800, China.
Irbesartan improves ventricular remodeling (VR) following myocardial infarction (MI). This study investigates whether irbesartan attenuates VR by reducing aldosterone production in the heart and its underlying mechanisms. MI was induced in male Sprague-Dawley rats through coronary artery ligation.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Convergence Medical Science, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Background: Huntington disease (HD), a neurodegenerative autosomal dominant disorder, is characterized by involuntary choreatic movements with cognitive and behavioral disturbances. Up to now, no therapeutic strategies are available to completely ameliorate the progression of HD. has various pharmacologic effects such as antioxidant and anti-inflammatory activities.
View Article and Find Full Text PDFJ Health Econ Outcomes Res
December 2024
Jazz Pharmaceuticals UK Ltd., London, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!